Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage

Table 3 Comparison between responders and non-responders in both hepatitis C groups (mean ± SD)

Variable	Group A (PEG-IFN+RBV) n = 38			Group B (IFN+RBV) n = 35
	R1	NR2	SR3	R1	NR2	SR3
Age (yr)	44.7 ± 5.4	47.8 ± 7.9	44.2 ± 5.8	45.23 ± 5.2	45.6 ± 6.2	42.9 ± 4.6
Body mass (kg)	82.6 ± 10.2	79.7 ± 17.0	82.7 ± 9.8	74.6 ± 9.5	73.1 ± 6.6	77.3 ± 9.6
ALT (μkat/L)
Before treatment	2.559 ± 1.564	1.524 ± 0.082	2.757 ± 1.607	1.494 ± 0.432	1.810 ± 0.570	1.524 ± 0.515
After 3 mo	1.065 ± 0.980	1.095 ± 0.767	1.084 ± 1.039	0.405 ± 0.112	1.135 ± 0.741	0.487 ± 0.263
Baseline HCV RNA (MU/L)	473 934 ± 373 542	496 256 ± 667 356	472 444 ± 402 109	312 786 ± 185 583	361 857 ± 339 942	346 667 ± 207 364

¹Responders;

²Non responder;

³Sustained response.